Marhic C
Rev Fr Gynecol Obstet. 1991 Feb 25;86(2 Pt 2):209-12.
The success of treatment aimed at improving manifestations of venous insufficiency appears today to be closely linked to a therapeutic impact on blood viscosity and the macrorheological parameters upon which it depends. This double-blind placebo-controlled trial of troxerutine was designed to evaluate changes during treatment in rheological abnormalities in 60 women with vulval varicosities and venous insufficiency of the lower limbs, half in the context of premenstrual syndrome and half in pregnant women from the 4th month on. Initial examination revealed no significant difference between the treated and control groups from a clinical and rheological standpoint in the gynecological and obstetric categories. Analysis of results showed that a high dose of troxerutine was associated with a very marked improvement in symptomatic parameters by the first month of treatment with a significant correlation between clinical criteria and rheological parameters in pregnant women as well as in those with a premenstrual syndrome. These data were confirmed by excellent acceptability as well as subjective assessment by patients after 4 months' treatment at the dosage of 4 g/d.
如今,旨在改善静脉功能不全表现的治疗成功与否,似乎与对血液粘度及其所依赖的宏观流变学参数的治疗作用密切相关。这项关于曲克芦丁的双盲安慰剂对照试验旨在评估60名患有外阴静脉曲张和下肢静脉功能不全的女性在治疗期间流变学异常的变化情况,其中一半处于经前综合征背景下,另一半为从第4个月起的孕妇。初始检查显示,从临床和流变学角度来看,治疗组和对照组在妇科和产科类别上并无显著差异。结果分析表明,高剂量曲克芦丁在治疗第一个月时,与症状参数的显著改善相关,在孕妇以及患有经前综合征的女性中,临床标准与流变学参数之间存在显著相关性。在以4克/天的剂量治疗4个月后,患者的良好耐受性以及主观评估证实了这些数据。